Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.47	$4.44	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$58.46M	1.52	84,300 shs	65,715 shs
MNPR Monopar Therapeutics	$32.06 +0.7%	$37.89	$2.25 ▼ $54.30	$197.81M	1.05	29,672 shs	70,898 shs
PRQR ProQR Therapeutics	$2.26 +2.3%	$2.13	$1.07 ▼ $4.62	$237.78M	0.43	290,003 shs	460,691 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	0.00%	-1.54%	-1.11%	+9.02%	-74.31%
DTIL Precision BioSciences	0.00%	+5.31%	-0.80%	+8.30%	-49.54%
MNPR Monopar Therapeutics	0.00%	-10.22%	-31.52%	-9.56%	+1,142.64%
PRQR ProQR Therapeutics	0.00%	+10.24%	0.00%	+35.33%	+7.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.0148 of 5 stars	2.9	0.0	0.0	1.8	1.7	1.3
DTIL Precision BioSciences	3.6332 of 5 stars	3.5	1.0	4.6	0.6	1.7	0.6
MNPR Monopar Therapeutics	2.7295 of 5 stars	3.4	4.0	0.0	2.0	2.5	0.0
PRQR ProQR Therapeutics	2.8265 of 5 stars	3.6	5.0	0.0	3.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	87.15% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	253.98% Upside

Current Analyst Ratings Breakdown

Latest DTIL, MNPR, CRGX, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
DTIL Precision BioSciences	$68.70M	0.85	N/A	N/A	$6.87 per share	0.72
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.62	N/A	N/A	$0.91 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	11/11/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$8.81	0.00	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.33	0.00	N/A	N/A	N/A	-41.76%	-39.49%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.46	0.00	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)

Latest DTIL, MNPR, CRGX, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	12.37	12.37
DTIL Precision BioSciences	0.66	5.18	5.18
MNPR Monopar Therapeutics	N/A	33.93	33.93
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
DTIL Precision BioSciences	37.99%
MNPR Monopar Therapeutics	1.83%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
DTIL Precision BioSciences	4.00%
MNPR Monopar Therapeutics	20.50%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
DTIL Precision BioSciences	200	11.79 million	11.32 million	No Data
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

DTIL, MNPR, CRGX, and PRQR Headlines

Recent News About These Companies

1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plc

August 24 at 4:07 AM | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

August 20, 2025 | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts

August 19, 2025 | americanbankingnews.com

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital

August 9, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 8, 2025 | marketbeat.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, MNPR, CRGX, and PRQR Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 08/22/2025 06:31 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Monopar Therapeutics NASDAQ:MNPR

$32.06 +0.22 (+0.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$32.06 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

ProQR Therapeutics NASDAQ:PRQR

$2.26 +0.05 (+2.26%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.34 +0.08 (+3.54%)

As of 08/22/2025 06:39 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time